arrow
L

Larry W. Kwak

pepromene bio
H指数:73
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

B-cell activating factor receptor expression in B-lymphoblastic leukaemia: Flow cytometric analysis and implications for targeted therapy

B细胞活化因子受体在B淋巴母细胞白血病中的表达:流式细胞术分析及其靶向治疗意义

2026-08-210
PRE
Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell Lymphoma

Polatuzumab Vedotin 联合 R-ICE(PolaR-ICE)作为弥漫性大B细胞淋巴瘤的二线治疗方案

2026-03-170
PRE
Bispecific BAFF-R/BCMA CAR T cells control growth of heterogeneous plasma cells in multiple myeloma

双特异性BAFF-R/BCMA CAR T细胞控制多发性骨髓瘤中异质性浆细胞的生长

2025-12-090
OAAI
Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration

Polatuzumab vedotin在CNS淋巴瘤中的应用:关于血脑屏障穿透的可行性研究

2025-10-100
OAAI
A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

一项Loncastuximab Tesirine联合Mosunetuzumab治疗复发/难治性弥漫大B细胞淋巴瘤的II期研究

BLOOD
IF23.1
2024-11-050
PRE
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study
2024-09-012
PRE
Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial
2024-08-112
OAAI
Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial
2023-01-0123
OAAI